Toggle navigation
Home
Feed
Channels
Profile
Home
Feed
Channels
Profile
Medspoke's Talks
Medspoke
Medspoke
Clinical Cancer Research
Published October 21, 2026
Carboplatin Plus Mirvetuximab Soravtansine In Platinum-Sensitive Ovarian Cancer: A Phase 2 Nonran...
October 23, 2026
Medspoke
Medspoke
Clinical Cancer Research
Published October 21, 2026
00:00
--:--
HexaBody-OX40 promotes antitumor immunity through FcγR crosslinking-independent OX40 agonist acti...
October 23, 2026
Share
HexaBody-OX40 promotes antitumor immunity through FcγR crosslinking-independent OX40 agonist activity and enhances effects of PD-1 blocking antibodies.
https://www.medspoke.co/channel_journal?id=686&tap_id=16124
Copy Link
Email
X
Bluesky
WhatsApp
LinkedIn
Facebook
Reddit
Medspoke
Medspoke
Annals of Oncology
Published October 21, 2026
The ESMO Scale for Clinical Actionability of Molecular Targets, version 2 (ESCAT v2): an evidence...
October 23, 2026
Why are you reporting this TALK?
